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used (proxy for comorbidity). Given the skewed distribution of
expenditure variables, multiple model speciﬁcations including
ordinary least squares regression, generalized linear model
(GLM) with Poisson, gamma and negative binomial variance
functions were evaluated. RESULTS: The prevalence of current
asthma among children in 2004 was estimated at 9.09%, i.e.,
6.7 million persons (95% CI: 8.27% to 9.99%) in the U.S. A
majority of children with asthma were male (61.6%), white
(68.1%), and insured (95.2%) with mean age of 8.9  0.25
years and education of 2.4  0.17 years. Children with asthma
had 69% higher total expenditures than non-asthmatics after
controlling for covariates (RR: 1.69; p < 0.0001). The annual
adjusted mean incremental total expenditure associated with
asthma was $661.7 (SE: $159.3; p < 0.0001) per person. Medi-
cations accounted for the largest proportion of the total expen-
ditures estimated at $197.9 (SE: $28.8; p < 0.0001), followed
by physician ofﬁce visits at $162.3 (SE: $57.7; p = 0.005) and
inpatient visits at $105.0 (SE: $75.9; p = 0.0167). CONCLU-
SION: Given the prevalence of asthma in children and its
associated incremental expenditures, the annual direct medical
expenditure for treating asthma in children is estimated at
approximately $4.4 billion in 2005 USD.
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OBJECTIVE: Cigarette smoking is one of the leading avoidable
causes of death in the world. However, in many countries, such
as Brazil, medications used during pharmacological treatments
are not supported by private or public health systems. The
purpose of this study is to analyze and to compare the ﬁnancial
impact of the costs related to adult smokers beneﬁciaries of a
health plan and deﬁne the best strategies to stimulate smoking
cessation programs. METHODS: We analyzed smoking habits,
based on an epidemiologic investigation of 46,407 beneﬁciaries
of a private health plan in Brazil. Expenses with hospitalization
and use of medical services during a period of 12 months, of
beneﬁciaries who report a daily smoking habit were compared
with those of non-smokers. Simulated analysis were performed
with the estimate costs of treatments with anti nicotin drugs a
potential decrease of the costs of the heath plan was estimated.
RESULTS: Among the beneﬁciaries, 29.0% (n = 10,270) were
smokers and 61.8% of those were male. The majority (86.7%) of
the smokers informed to consume 20 cigarettes per day; 9.5%
consumed 20 to 40 cigarettes per day and the rest of the group
(3.8%) consumed more than this amount. 43.3% smoked for less
than 10 years; 25.0% from 10 to 20 years and 31.6% for more
than 20 years. The prevalence of chronic diseases was higher
among the smokers, compared to non-smokers, as well as
average per capita cost expenditures (29% more than the non-
smokers). CONCLUSION: Starting from reported efﬁciency of
the nicotine replacement therapies added to psychological
support, applied to the group of smokers of the health plan and
comparing the costs of this strategy with the effective costs of
those beneﬁciaries, evidences demonstrate the importance of
considering ﬁnancial support systems to smoking cessation
interventions, by the health plan.
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OBJECTIVES: Asthma treatment guidelines and recent cost-
effectiveness models have shifted away from lung function out-
comes and moved toward emphasizing control. We developed
and validated a ﬂexible and transparent adult asthma policy
model that represents disease progression though levels of
asthma control and projects lifetime mortality, morbidity, and
costs. METHODS: We estimated uncertainty and point estimates
of model inputs for non-death transition state probabilities and
health state speciﬁc utilities and health care resource utilization
based on a rigorous analyses of a 3-year, multicenter, observa-
tional study of 4756 patients with difﬁcult-to-treat or severe
asthma receiving standard-of-care. We used statistical regression
models to test and account for population heterogeneity. We
validated the model following the ISPOR Task Force recommen-
dations. Three hypothetical scenarios were compared to
standard-of-care that resulted in different target product proﬁle
and pricing bands: A) a 30% relative reduction in exacerbation
rates with a $2000 per annum treatment cost; B) A plus a
threefold increased risk of asthma related death for the sub-
optimally controlled; C) B plus an absolute improvement in
utility by 0.02 for each health state. RESULTS: Simulation
cohorts, stratiﬁed by age and severity, transitioned through three
mutually exclusive levels of control until reaching death. Nine
health states were modeled because one cycle of control history
was predictive of present cost and utility. Compared to standard-
of-care, the three hypothetical scenarios resulted in societal
perspective incremental cost-effectiveness ratios of $284,000 per
QALY gained (95% interval: $193,000, $463,000), $263,000/
QALY (95% interval: $179,000, $422,000), and $62,000/QALY
(95% interval: $52,000, $72,000) respectively. CONCLU-
SIONS: This policy model adds to past asthma models because
its structure and inputs were based on current clinical guidelines
and a large long-term patient-level registry. This versatile model
can forecast: lifelong burden of disease, value of current and
emerging interventions, and parameters that yield the highest
return from further study.
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OBJECTIVE: This paper contributes to the debate on how
process affects reliability of scientiﬁc evidence in health care. It
discusses the use of different types of study designs in medicine
and biology versus social sciences to raise scientiﬁc international
evidence. METHODS: A comparison of study designs used in
clinical research (RCT and bridges studies (e.g. Hsiao CF et als,
2007)) and in social sciences. Examples from clinical sciences are
on environmental medicine and bridging studies. Examples from
social sciences are presented on two characteristics of six Euro-
pean hypertensive patient surveys on cost of medicines (ENDEP-
Lux, 2000): exemption criteria and classiﬁcation of medicines for
reimbursement. RESULTS: The comparison of case studies
shows similar problems for both clinical and ﬁnancing study
designs: imbalance of sample sizes between new and original sites
for clinical bridges studies, and between national sampled
patients with different access to health beneﬁts for ﬁnancing
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